Vladimir Startsev

Уролог, профессор,
#Urologist, Professor of #OncologyDept., #Researcher, Oncological and Reconstructive urology, Husband, Grandfather

[Journal of Urology @JUrology]

Can baseline testosterone levels help predict which prostate cancer patients on active surveillance are at higher risk of progression?

In this article, researchers found that low testosterone (≤300 ng/dL) was linked to increased risk of higher-grade progression (GG3 or above), suggesting it may be a valuable prognostic marker to guide surveillance and treatment decisions.

🔗 Click to read more: https://t.co/CwjENsPNc6

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Testosterone replacement therapy after surgery for #prostatecancer🚨

@JAMAInternalMed

⭐️SPIRIT trial

📊 RCT, n=136, low/int-grade PCa, post-RP, hypogonadal men
⏱️ TRT started ≥2 yrs post-RP w/ undetectable PSA
💉 12 wks testosterone vs placebo
✅ ↑ sexual activity (+0.9 events/day), desire, lean mass, VO₂ peak
🛡️ ZERO biochemical recurrences

⚠️ Short-term, proof-of-concept.
👉Bigger/longer trials including patients with higher-risk disease needed

@PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes

🔗https://t.co/nPtK3EahPQ

[IJIR: Your Sexual Medicine Journal @yoursexmedjour]

Outcomes of adult acquired buried penis (AABP) reconstruction: a multicentre cohort study 👉https://t.co/brzcCqFVwI

@N_Plamadeala @donwglee @drMirkoPreto @AngelodiGiova @drMarcoFalcone1 @paolo_gontero

[Fernando GomezSancha @fgomsan]

This paper relates membranous urethral length to postoperative stress urinary incontinence after HoLEP... It kind of blames the patient's anatomy for the occurrence of postoperative stress incontinence. I think with these incidences of post-op incontinence, the surgical technique used by the authors is a huge problem. Or is it that I only operate on patients with long urethral lengths to get way much lower rates of incontinence? (49,7% SUI at 1 month shows a flaw with surgical technique)

[UroToday.com @urotoday]

Real-world outcomes of bladder-sparing strategies for BCG-unresponsive #NMIBC: A multicenter study. Presentation by Pietro Scilipoti, MD @SanRaffaeleMI. #EAU26 written coverage by @RKSayyid @UAUrology > https://t.co/16Eq3UN1xe @Uroweb

[UroToday.com @urotoday]

#EAU26 State-of-the-art lecture BCG-naïve #NMIBC in 2025: Are we moving beyond BCG alone? Presentation by @evanguelosx. #EAU26 written coverage by @chavarriagaj > https://t.co/frpGwH2wpE @Uroweb

[UroToday.com @urotoday]

Biochemical recurrence and safety in patients with high-risk localised #ProstateCancer treated with [¹⁷⁷Lu]Lu-PSMA-617 prior to prostatectomy: Follow-up of the #LuTectomy trial. Presented by David Hennes, MD, BSc, DipSurgAnat @PeterMacCC. #EAU26 written coverage by @RKSayyid @UAUrology > https://t.co/MQm9PQNCsp @Uroweb

[Sagar Patel, MD @SagarRPatelMD]

Let's improve the treatment for histologic subtypes in MIBC! @UroDocAsh @ASCO

🧬Molecular profile is distinct
🚩Accurate classification of subtype is important (central pathology review)
✍️Thorough reporting of histologic subtypes in trials

https://t.co/ptWr2RDuCE

[Yakup Ergün @dr_yakupergun]

ASCO Educational Book

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms

(The results were not included in this paper; however, based on EV-304, we now know that EV + pembrolizumab is also a highly effective regimen in cisplatin-eligible patients)
https://t.co/ghCLZe2loo

[UroToday.com @urotoday]

#SunRISe1 Cohort 4 analysis: One-year disease-free survival in BCG-unresponsive papillary #BladderCancer. @siadaneshmand @KeckMedicineUSC joins @UroDocAsh @MDAndersonNews sharing SunRISe-1 Cohort 4 results for INLEXZO™ (Gem-iDRS) in BCG-unresponsive papillary #NMIBC—74% disease-free survival at 12 months, only 1 progression to MIBC, and 91% cystectomy-free survival at 18 months. Device placement success was 99.8% with QoL maintained. #WatchNow on UroToday > https://t.co/s3t0D7EEfE @UroOnc

[China pulse 🇨🇳 @Eng_china5]

China’s achievement
Only 90 grams!
Lighter than an apple!
The world’s lightest fully magnetic‑levitation artificial heart is now in service to benefit humanity.

[Andrea Apolo, M.D. @apolo_andrea]

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

[European Urology Oncology @EurUrolOncol]

Now published! 📰

Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study by Garvey Mezepo et al.

Read the full article here: https://t.co/2XfRw5V8K3

@uroweb
@mroupret
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@UroDocAsh
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

#Oncology #UroOncology #elsevier #scientificcommunity #europeanurologyoncology #academicpublishing #eau #urology #UrologyResearch #scientificpublication

[Vladimir Startsev @uro_star]

@Adam_Weiner535 Well done, very important direction of scientific and clinical research. Please, send me the link with the article

[Adam B. Weiner, MD @Adam_Weiner535]

📊 #CancerStats 2026 — #ProstateCancer Highlights

📈 ~2,114,850 new cancer cases & ~626,140 deaths projected in the U.S. this year

🧠 Prostate cancer remains one of the most diagnosed cancers in men, with rising incidence in recent years.

🩺 Prostate 5-yr survival is now among the highest (~98%), thanks to early detection & better treatments.

⚖️ Prostate cancer is the 2nd leading cause of cancer death in U.S. men after lung cancer.

📊 Death rates have declined ~50% since the early 1990s, but disparities persist (higher mortality in Black men)

🔥 Big picture: survival is up, mortality down — but rising advanced-stage diagnoses and inequities show there’s more work ahead.

🔗https://t.co/GlsjBdZTqb

💡 #ProstateCancer #Oncology #CancerStats2026 @PCFnews @UroOnc @AmericanCancer

[Yüksel Ürün @DrYukselUrun]

Modern medicine doubled human life expectancy in 200 years, not luck, but science. Thanks to vaccines, screenings, and now mRNA unlocking cancer cures.
As @elonmusk said: longevity is ‘extremely solvable’.
Optimism + evidence = progress. Err on hope, it improves the days that matter.
Grateful for breakthroughs ahead. 🚀🩺
#Longevity #mRNA #Cancer #Science @OurWorldInData @DeryaTR_ @DrNeilStone @grok #Davos2026

[UroToday.com @urotoday]

An #ArtificialIntelligence predictive biomarker for response to BCG vs gemcitabine-docetaxel for high-grade #NMIBC. @VigneshPackiam @RutgersCancer joins @UroDocAsh @MDAndersonNews to discuss an artificial intelligence test that analyzes digitized H&E slides from the index TURBT, examining over 600 microscopic features, including immune signatures, stromal features, and nuclear characteristics to predict patient response to treatment. #WatchNow > https://t.co/Z7sdidixBl

[Vladimir Startsev @uro_star]

Very interesting article, to my mind https://t.co/UXTDAEa0uz

[DrG @DocGauhar]

All u need to know about #optilume
https://t.co/DpnNMjlwIJ
https://t.co/KBCSl9fXa3
@trwherrmann @D_Castellani @steffiyuen @DeanElterm56241 @carlo_giulioni @Urologeman @wroclawski_uro @angelocafarell5 @A_Cormio @jteoh_hk
#UroSoMe @SpringerNature #BMCUrology @Uroweb @AmerUrological @Endo_Sec_Eua @Endo_Society @BAUSendourology @SauUrologia @UroAcademic @EAU_YAUroTech @ESRUrology @Dmitry_Enikeev @GiacomoPirola

[Laura Bukavina @LauraBukavinaMD]

New pub alert 🚨 The bladder microbiome may influence intravesical chemotherapy response in bladder cancer. 🦠💊
🧪 we tested uropathogenic E. coli (UPEC) and gemcitabine
Results>
• Ecoli can enter tumor cells (of course)
• Inactivate gemcitabine → converting it to an inactive metabolite (dFdU)
• Reduce chemo’s ability to kill cancer cells ‼️.. think about 🥨 #TAR200 #microbiome #BladderCancer
https://t.co/nLtp2v4Gds @RGin110 @uretericbud @MSindhani Phil Abbosh